FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/02/2024
Voltar para busca
Dado oficial do USPTO
ROHTONITTEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
05/02/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
08/09/2021
Data de registro
17/10/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/10/2023
Última transação
17/10/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
JP
Examinador
CALLOWAY, CHRISTINA DENISE
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of stylized blue wording "ROHTONITTEN". The color white represents background and/or transparent areas and is not a feature of the mark.
Titulares e representantes
Titulares
Rohto Pharmaceutical Co., Ltd.
Representantes
Sandra Epp Ryan Hamre, Schumann, Mueller & Larson, P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
In-vitro diagnostic drugs; eye wash bactericides; medicated eye ointments; contact lens cleaning preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments for treatment of eye disease; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula ; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; eye drops for treatment of eratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Analgesics; antipyretic preparations; antibiotics; athletes' foot preparations; medicinal drinks; medicinal hair growth preparations; motion sickness treatment preparations; pharmaceutical preparations for treating diabetes; preparations for treating colds; reagent paper for medical purposes; collyrium; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babiesliquid formula milk for babies; food for babies; dietary supplements; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; capsules sold empty for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages for skin wounds; breast-nursing pads; cotton swabs for medical use; dental porcelainmaterials; dental impression materials; dental composite materials; diapersincontinence diapersbaby diapers; infant diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; semen for artificial insemination
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/01/2024
FIMP
FINAL DISPOSITION PROCESSED
18/01/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/01/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
17/10/2023
GPNX
NOTIFICATION PROCESSED BY IB
14/08/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/08/2023
PUBO
PUBLISHED FOR OPPOSITION
01/08/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/07/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/06/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
26/06/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
26/06/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
26/06/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/05/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
17/05/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
29/11/2022
GNFR
FINAL REFUSAL E-MAILED
29/11/2022
CNFR
FINAL REFUSAL WRITTEN
29/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/11/2022
RFNT
REFUSAL PROCESSED BY IB
19/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/06/2022
RFRR
REFUSAL PROCESSED BY MPU
30/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/06/2022
CNRT
NON-FINAL ACTION WRITTEN
15/06/2022
DOCK
ASSIGNED TO EXAMINER
13/06/2022
MAFR
APPLICATION FILING RECEIPT MAILED
21/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ROHTONITTEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.